• P.S.K. Biosciences, initially a drug delivery platform team within Simcere Pharmaceutical Group Limited, launch in 2021. With backing from Lenovo Capital, local government investment grants, we became independent and have been advancing exosome-based drug development.

• We are dedicated to tissue tropism drug delivery using exosomes, specifically for penetrating the blood-brain-barrier (BBB) with siRNA drug loading and mRNA drug carriers. We have achieved significant breakthroughs in loading drugs into exosomes through advanced genome editing technologies and have overcome the bottleneck in large-scale manufacturing of exosome-shRNA/mRNA, thereby addressing a key challenge in the field.

• We are redefining treatment possibilities with human mesenchymal stem cell -derived exosomes (MSC-exo) sub-groups: POI, IPF, IBD, AD, Stroke, and PD. Our unique sub-groups of human MSC-exo offer better efficacy for different indications, and present differentiated innovation opportunities.